Abstract
Background Chikungunya is an emerging epidemic-prone vector-borne disease of considerable significance globally. Infection with chikungunya virus induces an acute illness characterized by fever and painful arthralgia, which can evolve to chronic arthritis and rheumatism especially in elderly patients. Whereas febrile illness and arthralgia are common clinical presentations amongst residents of Mt. Elgon, the role of chikungunya virus as a causative agent is undocumented. This study was carried out to determine the prevalence of IgA, IgM and IgG antibodies against Chikungunya Virus (CHIKV) antigens in patients presenting with acute febrile illnesses in Mt. Elgon region, Kenya.
Methods This was a cross-sectional seroprevalence study on febrile patients visiting Endebes, Andersen and Kitale County Referal Hospitals. Sociodemographic data was collected whenever possible. Serum samples were collected and screened using Indirect ELISA for 1gG+IgM+IgA antibodies. Sera that tested positive by ELISA were subjected to standard plaque reduction neutralization assays (PRNT) performed on monolayer cultures of Vero E6 cells for confirmation.
Results By ELISA, a total of 317/1359 (23.33%) sera were positive for CHIKV antibodies. Of the 317 positive sera, 305 (96.21%) were of sufficient quantity and were subjected to PRNT. Ultimately, 127 (9.3%) samples tested positive for CHIKV neutralising antibodies by PRNT.
Conclusion These findings suggest active circulation of CHIKV in Mt. Elgon, even though it has previously been considered a non-endemic region for the virus. There is need to closely monitor and continuously put in place surveillance strategies to prevent probable potential outbreaks in the future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study protocol was sought from Kenya Medical Research Institute Ethical Review Committee under Scientific Steering Committee No.1698. Parental/guardian consent was sought for participants under 17 years of age.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All the data is in the manuscript. However, any extra data, if required can be made available on request.
